Table 4.
Univariate logistic regression analysis of factors associated with the development of any grade ≥ 3 hematologic toxicity
| Parameter | Odds ratio | 95% CI | P value |
|---|---|---|---|
| Age (years) | 1.000 | 0.972–1.029 | 0.991 |
| BMI (kg/m2) | 0.982 | 0.898–1.074 | 0.982 |
| Duration of EBRT (days) | 1.069 | 0.987–1.158 | 0.102 |
| Clinical stage (FIGO2018) | 1.759 | 0.964–3.208 | 0.066 |
| Histology | 0.559 | 0.232–1.345 | 0.194 |
| Differentiation degree | 0.789 | 0.431–1.445 | 0.443 |
| PTV dose-pelvis | 1.696 | 0.930–3.094 | 0.085 |
| Cycles of chemotherapy | 1.056 | 0.861–1.295 | 0.600 |
| Volume (cm3) | 1.002 | 1.000–1.004 | 0.053 |
| Chemotherapy regimen | |||
| TP | 0.027* | ||
| Carboplatin | 0.257 | 0.094–0.701 | 0.008* |
| Cisplatin | 0.442 | 0.198–0.987 | 0.046* |
| TPB_V10 | 1.197 | 1.109–1.292 | < 0.001* |
| TPB_V20 | 1.176 | 1.109–1.248 | < 0.001* |
| TPB_V30 | 1.102 | 1.057–1.149 | < 0.001* |
| TPB_V40 | 1.114 | 1.055–1.177 | < 0.001* |
| TPB_V50 | 1.142 | 1.069–1.221 | < 0.001* |
BMI, body mass index; EBRT, pelvic external-beam radiotherapy; TPB_V10, TPB_V20, TPB_V30, TPB_V40, TPB_V50 = the total pelvic bones of volume receiving 10,20, 30, 40, 50 Gy; TP, paclitaxel + cisplatin. Bold indicates the significant values (*P < 0.05)